We can't find the internet
Attempting to reconnect
Something went wrong!
Hang in there while we get back on track
Performance of preclinical models in predicting drug-induced liver injury in humans: a systematic review
Summary
Researchers systematically reviewed animal and human trial data on two diabetes drugs to assess how well preclinical tests predicted real-world liver toxicity, finding that standard animal studies failed to flag troglitazone's serious liver risks — while in vitro (lab-based) cell testing showed clear differences in the two drugs' toxic profiles. The findings argue for using mechanistic lab data earlier in drug development to prevent harm that animal tests alone may miss.
Drug-induced liver injury (DILI) causes one in three market withdrawals due to adverse drug reactions, causing preventable human suffering and massive financial loss. We applied evidence-based methods to investigate the role of preclinical studies in predicting human DILI using two anti-diabetic drugs from the same class, but with different toxicological profiles: troglitazone (withdrawn from US market due to DILI) and rosiglitazone (remains on US market). Evidence Stream 1: A systematic literature review of in vivo studies on rosiglitazone or troglitazone was conducted (PROSPERO registration CRD42018112353). Evidence Stream 2: in vitro data on troglitazone and rosiglitazone were retrieved from the US EPA ToxCast database. Evidence Stream 3: troglitazone- and rosiglitazone-related DILI cases were retrieved from WHO Vigibase. All three evidence stream analyses were conducted according to evidence-based methodologies and performed according to pre-registered protocols. Evidence Stream 1: 9288 references were identified, with 42 studies included in analysis. No reported biomarker for either drug indicated a strong hazard signal in either preclinical animal or human studies. All included studies had substantial limitations, resulting in "low" or "very low" certainty in findings. Evidence Stream 2: Troglitazone was active in twice as many in vitro assays (129) as rosiglitazone (60), indicating a strong signal for more off-target effects. Evidence Stream 3: We observed a fivefold difference in both all adverse events and liver-related adverse events reported, and an eightfold difference in fatalities for troglitazone, compared to rosiglitazone. In summary, published animal and human trials failed to predict troglitazone's potential to cause severe liver injury in a wider patient population, while in vitro data showed marked differences in the two drugs' off-target activities, offering a new paradigm for reducing drug attrition in late development and in the market. This investigation concludes that death and disability due to adverse drug reactions may be prevented if mechanistic information is deployed at early stages of drug development by pharmaceutical companies and is considered by regulators as a part of regulatory submissions.
Sign in to start a discussion.
More Papers Like This
Predicting Valproate-Induced Liver Injury Using Metabolomic Analysis of Ex Ovo Chick Embryo Allantoic Fluid
This paper is not about microplastics; it evaluates chick embryo allantoic fluid metabolomics as a model for predicting drug-induced liver injury from valproate.
Can the impact of micro- and nanoplastics on human health really be assessed using in vitro models? A review of methodological issues
This review examines whether lab-based cell studies can reliably predict how micro and nanoplastics affect human health. The authors found significant inconsistencies in how researchers choose plastic particle types, doses, and exposure methods, making it hard to compare results across studies. The paper calls for standardized testing protocols so that lab findings can more accurately reflect real-world microplastic exposure risks to people.
Microplastic-induced hepatic adverse effects evaluated in advanced quadruple cell human primary models following three weeks of repeated exposure
Scientists tested the effects of microplastics on a sophisticated model of human liver cells over three weeks of repeated exposure, finding that certain microplastic types triggered inflammation and altered liver function. The advanced cell model, which combines four types of human liver cells, provides more realistic results than simpler lab tests. These findings add to growing evidence that microplastics accumulating in the liver could contribute to chronic inflammation and liver damage in humans.
Transforming Toxicity Assessment through Microphysiology, Bioprinting, and Computational Modeling
This review examines emerging alternatives to traditional animal-based toxicity testing, including microphysiology systems, bioprinted tissues, and computational models. Researchers found that these human cell-based platforms can better predict how chemicals and drugs affect human biology while also being more ethical and higher throughput. The study suggests these technologies could transform how chemical safety and drug development testing is conducted.
A computational framework for multi-scale data fusion in assessing the associations between micro- and nanoplastics and human hepatotoxicity
Researchers developed a computational toxicology framework integrating multi-source data and network analysis to map associations between micro- and nanoplastics and hepatotoxicity, identifying key molecular pathways through which MNPs may damage the liver, offering a scalable alternative to traditional in vivo testing.